JAK2 and breast carcinoma: The pre-clinical assessment of JAK2 inhibition in combination with SMO-GLI1/tGLI1 inhibitors demonstrated the synergistic inhibition of primary tumor growth and metastasis, prolonging survival in rodent breast cancer models [43].